Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANNX
STRONG SELLAnnexon, Inc. · Healthcare · United States · $855M · Avg Vol: $24M/d
COMPANY DESCRIPTION
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing novel C1q and classical complement pathway inhibitors to treat a range of autoimmune, neurodegenerative, and ophthalmic diseases. The company's proprietary antibody platform targets a specific component of the immune system, aiming to halt disease progression by preventing complement-mediated damage. Its competitive edge lies in its pioneering scientific approach to complement biology and the potential breadth of its therapeutic applications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 37.8M | — |
| EPS | -3.40 | -0.76 | -0.85 | -1.01 | -1.34 | — | -1.15 | -0.98 | -0.96 | — |
| Shares | 38.6M | 163.8M | 163.8M | 109.4M | 149.4M | +287.3% | 163.8M | — | — | — |
| Debt | 34.6M | 32.9M | 31.4M | 29.0M | 26.2M | -6.7% | 25.4M | — | — | — |
| Equity | 231.9M | 231.2M | 250.6M | 293.1M | 211.6M | -2.3% | — | — | — | — |
| Op CF | -106.1M | -116.3M | -121.1M | -118.0M | -186.4M | — | -183.1M | — | — | — |
| Inv CF | -88.2M | 58.4M | 70.7M | -218.8M | 190.1M | — | — | — | — | — |
| Fin CF | 1.8M | 122.9M | 135.5M | 161.2M | 108.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANNX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANNX | Annexon, Inc.(you) | $855M | 16 | STRONG SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 19 | STRONG SELL |
| DRUG | Bright Minds Biosciences Inc. | $700M | 17 | STRONG SELL |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $707M | 17 | STRONG SELL |
| KURA | Kura Oncology, Inc. | $922M | 20 | STRONG SELL |
| ACHV | Achieve Life Sciences, Inc. | $626M | 17 | STRONG SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 18 | STRONG SELL |
| VOR | Vor Biopharma Inc. | $1.0B | 14 | STRONG SELL |
| ACRS | Aclaris Therapeutics, Inc. | $730M | 20 | SELL |
| SGP | SpyGlass Pharma, Inc. | $685M | 13 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%